Generate Biomedicines Inc
GENBNASDAQStock · Data from SEC EDGAR 13F · Held by 3 of 87 tracked investors
Generate Biomedicines Inc at a glance
An overview of the financial statements, in plain language. Switch to the advanced view for charts.
- Valuation15
- Growth10
- Profitability15
- Quality25
- Debt100
- Stability50
- ✓It has more cash than debt.
- ✓The analysts' average target is 104% above the price.
- !The company is loss-making: net profit is negative.
The score describes the quality and the past of the company based on its statements (the FinBoss model, indicative). A high score is not a buy signal and a low one is not a sell signal. Data source: Yahoo Finance, prices and statements in USD.
Is the stock expensive?
ExpensiveThe company has no earnings, so the P/E cannot be calculated.
- P/E
- –
- P/S
- 64.0×
- EV/EBITDA
- -4.8×
Is the company growing?
–Too few years to compare. Last year -37.7%.
Does it make money?
Loss-makingNet margin: 0.0%.
Is it financially healthy?
Yes- Cash
- 457M USD
- Debt
- 63M USD
- Free CF
Chart GENB
Insider purchases
last 90 days, SEC Form 4Which investors hold this stock
3HM Harvard Management Company Harvard Management Company | 0.44% |
CW Cathie Wood ARK Investment Management | 0.14% |
Ns Norský státní fond Norges Bank | 0% |
Frequently asked questions
How much is Generate Biomedicines Inc (GENB) stock?
Generate Biomedicines Inc shares trade at $13.21, +6.96% over the last trading day. The price is delayed.
What is the market cap of Generate Biomedicines Inc?
The market cap of Generate Biomedicines Inc is about $1.7B.
Which big investors hold Generate Biomedicines Inc?
According to the latest 13F filings, 3 of 87 tracked investors hold Generate Biomedicines Inc, for example Harvard Management Company, Cathie Wood, Norský státní fond.
Source: SEC EDGAR 13F-HR (quarterly filings). The data is indicative and is not investment advice.